Jérôme Meunier
Centre hospitalier universitaire d'Orléans(FR)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment
Most-Cited Works
- → Ophthalmologic and intraocular non‐Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors(2004)124 cited
- → Multicenter Outbreak of Infections by Saprochaete clavata , an Unrecognized Opportunistic Fungal Pathogen(2014)89 cited
- → Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer(2019)68 cited
- → Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group(2017)64 cited
- → Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial(2023)27 cited
- → Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors(2006)26 cited
- → Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer(2023)23 cited
- → Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study(2015)19 cited
- → Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.(2019)16 cited
- → Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer(2020)15 cited